Company intelligence / Profile preview

TransThera Biosciences

Ownership: Private
Employees: ~72
Development stage: Other

Overview

TransThera’s lead program tinengotinib has shown promising clinical benefit in patients with FGFR-altered metastatic cholangiocarcinoma who have progressed after prior FGFR inhibitor treatment. The company has presented positive early-phase results for its BTK inhibitor TT‑01488 in relapsed/refractory B-cell malignancies and continues to advance a pipeline of differentiated small molecule therapeutics targeting oncology and inflammatory diseases.

Therapeutic areas: OncologyMetabolic DisordersImmunologyHematology
Modalities: Small molecules (focus on innovative small molecule therapies)Kinase inhibitors (multi-targeted kinase inhibitors)NCE drugs (new chemical entities)
Industry: Biotech

Drug pipeline

7 assets

tinengotinib

6 more assets in the full pipeline.

Partnerships

In-license agreement with LG Chem for TT–01688 rights in Greater China.

Beyond the preview

Go deeper on TransThera Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TransThera Biosciences.